RNAi
Want a sneak peek into the Oligonucleotide Therapeutics market? Access the “Table of Content” of Oligonucleotide Therapeutics market report! https://www.persistencemarketresearch.com/toc/12787
Oligonucleotide Therapeutics Market: Region-wise Outlook
The presence of the main market leaders, market consolidation and commercialization of new molecules are all contributing towards the dominating position of North America in the oligonucleotides therapeutic market. Miragen Therapeutics, Inc. agreed to merge with Signal Genetics, Inc for an initial investment of USD 40 million. Through this merger both the companies expect to develop micro RNA-targeted oligonucleotide clinical products. New molecule application is also another strategy the market players are using to mark their presence in the oligonucleotide therapeutic market. Biogen recently received FDA approval for a new drug application for nusinersen. If approved, the antisense oligonucleotides molecule would be the first of its kind to be used for treating spinal muscular atrophy.